The Indian Medical Parliamentarians’ Forum (IMPF) convened the National Policy Summit on MedTech Access on September 22 at Meril Academy, Vapi, under the theme
Novo Nordisk is reshaping its GLP-1 strategy through oral pills, obesity prevention, and new markets as it expands beyond its injectable-led portfolio.
Anton Paar India has announced NEXUS, a new two-day Industry Knowledge & Technology Platform designed to bring together industry leaders, scientists, researchers and academia to exchange insights on some of the most pressing analytical and manufactur
On the occasion of World Alzheimer's Day, Yatharth Hospital, Sector 20, Faridabad, has launched the region’s first dedicated Memory Clinic aimed at providing comprehensive assessment, diagnosis and management for individuals experiencing memory loss
Pharma R&D dollars are spreading across biosimilars, combination therapies, and gene therapy, balancing near-term commercial returns with high-risk innovation.
Merck joins India’s crowded biomanufacturing push as global life-science suppliers expand local capacity, training infrastructure and customer support.
Pharma investment is accelerating across hospitals, biosimilars, manufacturing and healthcare infrastructure, revealing changing industry growth priorities.
Gilead just raised the bar in the long-acting HIV prevention race with expanded licensing for investigational once-yearly lenacapavir.
Dr. Reddy’s Laboratories enters India’s nivolumab race with Nivorz, adding biosimilar competition to the cancer drug market.
Lilly claims 30 percent share as the oral weight-loss race intensifies, challenging Novo Nordisk’s early lead in the growing obesity treatment market.
.jpg)
, CDSCO.jpg)
